Similar articles

• New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?

  Danese S, Angelucci E. Danese S, et al. Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S217-27. doi: 10.1016/S0399-8320(09)73157-4. Gastroenterol Clin Biol. 2009. PMID: 20117345 Review.
• Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses.

  Marchetti M, Liberato NL. Marchetti M, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):815-24. doi: 10.1586/14737167.2014.957682. Epub 2014 Sep 27. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 25262931 Review.
• [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2008 Dec 11;150(51-52):54-5. MMW Fortschr Med. 2008. PMID: 19156959 German. No abstract available.
• [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].

  Hellström PM, Schmidt D, Karlén P. Hellström PM, et al. Lakartidningen. 2007 Oct 10-16;104(41):2973-6. Lakartidningen. 2007. PMID: 17977308 Review. Swedish. No abstract available.
• [Biologicals in gastroenterology: TNF-blockers].

  Scharl M, Rogler G. Scharl M, et al. Dtsch Med Wochenschr. 2010 Nov;135(45):2243-52. doi: 10.1055/s-0030-1267508. Epub 2010 Nov 2. Dtsch Med Wochenschr. 2010. PMID: 21046532 Review. German.